Mitoquinone mesylate (Mitoquinone methanesulfonate) |
| Katalog-Nr.GC31292 |
Mitoquinone mesylate(Mitoquinone methanesulfonate) gehört zu den weit verbreiteten Antioxidantien, die auf die Mitochondrien abzielen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 845959-50-4
Sample solution is provided at 25 µL, 10mM.
Mitoquinone mesylate(Mitoquinone methanesulfonate) gehört zu den weit verbreiteten Antioxidantien, die auf die Mitochondrien abzielen. Es wurde entwickelt, um die Blut-Hirn-Schranke(BBB) und neuronale Membranen leicht zu durchdringen, wo es sich in den Mitochondrien um ein Vielfaches konzentriert und die lokale antioxidative Kapazität vermittelt[1]. Innerhalb der ETC reduziert Komplex II, auch bekannt als Succinat-Dehydrogenase, den Ubichinonrest von Mitoquinone mesylate zum aktiven Antioxidans Ubichinol, das überschüssige ROS abfängt[2].
Mitoquinone mesylate (50 nM) reduzierte die 6-OHDA-induzierte mitochondriale Fragmentierung in der SH-SY5Y-Zelllinie. Es hemmte das mitochondriale Spaltprotein und die Translokation des pro-apoptotischen Proteins(Bax) in den Mitochondrien[3].
Die Behandlung mit Mitoquinone mesylate hemmte den Verlust dopaminerger Neuronen und verbesserte die Verhaltensleistung. Sie zeigte neuroprotektive Effekte in Mausmodellen mit Parkinson-Krankheit(PD)[4]. Die Behandlung mit Mitoquinone mesylate verbesserte die Feinmotorik und reduzierte Marker für oxidative Schäden in der Muskulatur in einem Mausmodell mit Huntington-Krankheit(HD)[5]. Mitoquinone mesylate reduzierte Verletzungen der weißen Substanz, verbesserte die neurologische Leistung und verringerte die Latenz des motorisch evozierten Potenzials bei Mäusen mit intrazerebraler Hämorrhagie(ICH)[6].
References:
[1]. Murphy M P, Smith R A J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations[J]. Annu. Rev. Pharmacol. Toxicol., 2007, 47: 629-656.
[2]. James A M, CochemÉ H M, Smith R A J, et al. Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species: IMPLICATIONS FOR THE USE OF EXOGENOUS UBIQUINONES AS THERAPIES AND EXPERIMENTAL TOOLS*♦[J]. Journal of Biological Chemistry, 2005, 280(22): 21295-21312.
[3]. Solesio M E, Prime T A, Logan A, et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2013, 1832(1): 174-182.
[4]. Pinho B R, Duarte A I, Canas P M, et al. The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice[J]. Free Radical Biology and Medicine, 2020, 146: 372-382.
[5]. Pinho B R, Duarte A I, Canas P M, et al. The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice[J]. Free Radical Biology and Medicine, 2020, 146: 372-382.
[6]. Chen W, Guo C, Jia Z, et al. Inhibition of mitochondrial ROS by MitoQ alleviates white matter injury and improves outcomes after intracerebral haemorrhage in mice[J]. Oxidative medicine and cellular longevity, 2020, 2020.
| Zellexperiment [1]: | |
Zelllinien | HSC-T6-Zellen |
Vorbereitungsmethode | Mitoquinone mesylate wurde 24 Stunden lang in Endkonzentrationen von 2 µM, 20 µM, 13 µM, 50 n bzw. 10 µM direkt zum Kulturmedium hinzugefügt. |
Reaktionsbedingungen | 2 µM, 20 µM, 13 µM, 50 nM oder10 µM für 24 Stunden |
Anwendungen | Mittels konfokaler Fluoreszenzmikroskopie zeigte es, dass die Behandlung mit Mitoquinone mesylate fragmentierte Mitochondrien in aktiven HSCs in einen verlängerten Zustand zurückführte. Immunoblot-Analysen zeigten eine signifikante Herunterregulierung von Fis1 und Drp1 nach der Behandlung mit Mitoquinone mesylate. |
| Tierversuch [2]: | |
Tiermodelle | männliche Wistar-Ratten |
Vorbereitungsmethode | Für die pharmakokinetische Studie wurde Gruppen von Ratten (n = 4-5) entweder eine intravenöse (IV) Dosis (5 mg/kg) über die Kanüle oder eine orale Dosis(25 mg/kg) durch Schlundsonde verabreicht. |
Dosierungsform | Intravenöse Injektion, 5 mg/kg; oral, 25 mg/kg. |
Anwendungen | Nach oraler Gabe wurde Mitoquinone mesylate schnell resorbiert und erreichte nach etwa 1 Stunde eine Plasmakonzentration von etwa 25 ng/mL. Danach schwankte die Mitoquinone-mesylate-Konzentration und erreichte nach 4 Stunden ein Maximum(Cmax) von 31.2 ± 6.9 ng/mL. Nach IV-Gabe zeigte die Plasmakonzentration von Mitoquinone mesylate einen exponentiellen Abfall mit einer schnellen Verteilungsphase, gefolgt von einer langsameren Eliminationsphase. |
References: | |
| Cas No. | 845959-50-4 | SDF | |
| Canonical SMILES | [O-]S(=O)(C)=O.O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4C)C(OC)=C(OC)C4=O | ||
| Formula | C38H47O7PS | M.Wt | 678.81 |
| Löslichkeit | DMSO : 50 mg/mL (73.66 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4732 mL | 7.3658 mL | 14.7317 mL |
| 5 mM | 294.6 μL | 1.4732 mL | 2.9463 mL |
| 10 mM | 147.3 μL | 736.6 μL | 1.4732 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
MitoQ attenuated NLRP3-inflammasome activation and apoptosis in AlCl3-treated Parkin-/- mice hippocampus. (C) Effects of MitoQ on the apoptosis of mice hippocampus by TUNEL staining. The histogram represents the ratio of TUNEL-positive cells.
The second-time was treated with normal saline, MitoQ (5mg/kg body weight, twice weekly，GLPBIO, USA) or MCC950 by intraperitoneal injection in the afternoon of the same day.
Ecotox Environ Safe, 2023, 264: 115459. PMID: 37703808 IF: 6.7996 -
Related Biological Data
MitoQ alleviated mtROS overproduction, activation of NLRP3-inflammasome and W/β signaling, fibrosis and structural and functional damage in the T-2 animal model. (F, G) Protein levels of NLRP3, pro-IL-1β, and caspase-1 p20 in mice kidneys.
MitoQ (100μM, GLPBIO, USA), MCC950 (10μM), or ICG-001 (10μM) were added to the culture medium for 4h before exposing to T-2 media.
J Agr Food Chem (2022). PMID: 36239691 IF: 5.8954 -
Related Biological Data
(J) TUNEL staining of apoptosis.
The MitoQ (GLPBIO, USA) was intraperitoneally administered to mice in HFPO-TA + MitoQ group (5mg/kg, twice/week for 4 weeks).
Food Chem Toxicol (2023): 113706. PMID: 36871880 IF: 5.5716 -
Related Biological Data
ApoE4 exacerbates oxidative stress after oxyHb or SAH. (N-R) Western blots bands (N) of CD16, CD86, Arg-1 and CD206 in APOE4-PBS and APOE4-mitoQ, densitometric quantification of CD16 (O), CD86 (P), Arg-1 (Q) and CD206 (R).
Mitoquinone (GLPBIO, USA) was prepared by dissolving 5mg in dimethylsulfoxide (DMSO).
Neuroscience, 2023. PMID: 37290684 IF: 3.708
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *